
- ONCOLOGY Vol 20 No 6
- Volume 20
- Issue 6
NCI Director Nominated as New FDA Commissioner
NCI Director Nominated as New FDA Commissioner
President Bush has nominated NCI director Andrew C. von Eschenbach, MD, as commissioner of the Food and Drug Administration (FDA). Dr. von Eschenbach has served as acting FDA commissioner since the resignation of Lester M. Crawford, DVM, PHD, in September 2005. If confirmed by the Senate, Dr. von Eschenbach will become the third FDA commissioner under President Bush.
Dr. von Eschenbach joined NCI in January 2002 after a distinguished career as a urologic surgeon and cancer advocate at M. D. Anderson Cancer Center. Since his appointment as acting FDA commissioner, the day-to-day management of NCI has been overseen by chief operating officer John Niederhuber, MD, an arrangement that will continue until Dr. von Eschenbach is confirmed as FDA commissioner.
Articles in this issue
almost 20 years ago
FDA Clears Extended Dosing of Darbepoetin for Chemotherapy-Induced Anemiaalmost 20 years ago
Orphan Drug Status Granted to Sorafenib for Liver Canceralmost 20 years ago
Advanced Non-Small-Cell Lung Canceralmost 20 years ago
PROs: Defining Clinical Benefit From the Patient's Perspectivealmost 20 years ago
Commentary (Kelly/Goldberg): CEA Monitoring in Colorectal Canceralmost 20 years ago
CEA Monitoring in Colorectal Canceralmost 20 years ago
Defining Clinical Endpoints in Renal Cell CarcinomaNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.




































